International Journal of Science and Research (IJSR)
www.ijsr.net | Most Trusted Research Journal Since Year 2012

Research Paper | Medicine Science | Indonesia | Volume 9 Issue 3, March 2020

Breast Cancer Incidence in Diabetes Mellitus Patients on Insulin Glargine Compared with Human Neutral Protamine Hagedorn Insulin Treatment

Noviana Joenputri, Nia Novianti Siregar

Introduction: Observational studies evaluating the association between long-acting insulins and breast cancer incidence is limited. We conducted a systematic review to compare the incidence of breast cancer between diabetes mellitus (DM) patients on long-acting insulin treatment. Methodology: We systematically searched the literatures from MEDLINE, Science Direct and PROQUEST from 2008 to 2018 to identify all observational studies evaluating the relationship between use of insulin glargine and human Neutral Protamine Hagedorn (NPH) insulin to breast cancer incidence among patients with type-1 and/or type-2 diabetes mellitus (DM) aged ≥ 18 years old. The methodological aspects such as residual confounding and duration of follow-up were assessed. Results: A total of four cohort studies met our inclusion criteria. Follow-up duration ranged from 0.9 to 3.3 years. Two studies showed the use of insulin glargine was associated with an increased risk of breast cancer in comparison with human NPH insulin and two other studies found no evidence of breast cancer. All of these studies had a short follow-up duration and were not able to examine residual confounding. Conclusion: We found limited support for association of glargine use with increased breast cancer risk compared to human NPH insulin due to the methodological issues. Further studies with better methodological aspects are needed to explain the difference of breast cancer incidence between those treatments.

Keywords: diabetes mellitus, insulin analog, breast cancer

Edition: Volume 9 Issue 3, March 2020

Pages: 757 - 759

How to Cite this Article?

Noviana Joenputri, Nia Novianti Siregar, "Breast Cancer Incidence in Diabetes Mellitus Patients on Insulin Glargine Compared with Human Neutral Protamine Hagedorn Insulin Treatment", International Journal of Science and Research (IJSR), https://www.ijsr.net/search_index_results_paperid.php?id=SR20314094229, Volume 9 Issue 3, March 2020, 757 - 759

0 PDF Views | 0 PDF Downloads

Download Article PDF

Research Paper | Medicine Science | Indonesia | Volume 9 Issue 3, March 2020

Breast Cancer Incidence in Diabetes Mellitus Patients on Insulin Glargine Compared with Human Neutral Protamine Hagedorn Insulin Treatment

Noviana Joenputri, Nia Novianti Siregar

Introduction: Observational studies evaluating the association between long-acting insulins and breast cancer incidence is limited. We conducted a systematic review to compare the incidence of breast cancer between diabetes mellitus (DM) patients on long-acting insulin treatment. Methodology: We systematically searched the literatures from MEDLINE, Science Direct and PROQUEST from 2008 to 2018 to identify all observational studies evaluating the relationship between use of insulin glargine and human Neutral Protamine Hagedorn (NPH) insulin to breast cancer incidence among patients with type-1 and/or type-2 diabetes mellitus (DM) aged ≥ 18 years old. The methodological aspects such as residual confounding and duration of follow-up were assessed. Results: A total of four cohort studies met our inclusion criteria. Follow-up duration ranged from 0.9 to 3.3 years. Two studies showed the use of insulin glargine was associated with an increased risk of breast cancer in comparison with human NPH insulin and two other studies found no evidence of breast cancer. All of these studies had a short follow-up duration and were not able to examine residual confounding. Conclusion: We found limited support for association of glargine use with increased breast cancer risk compared to human NPH insulin due to the methodological issues. Further studies with better methodological aspects are needed to explain the difference of breast cancer incidence between those treatments.

Keywords: diabetes mellitus, insulin analog, breast cancer

Edition: Volume 9 Issue 3, March 2020

Pages: 757 - 759

How to Cite this Article?

Noviana Joenputri, Nia Novianti Siregar, "Breast Cancer Incidence in Diabetes Mellitus Patients on Insulin Glargine Compared with Human Neutral Protamine Hagedorn Insulin Treatment", International Journal of Science and Research (IJSR), https://www.ijsr.net/search_index_results_paperid.php?id=SR20314094229, Volume 9 Issue 3, March 2020, 757 - 759

0 PDF Views | 0 PDF Downloads

Download Article PDF

Video Lecture of Above Article is Not Available Yet

You be the First to Request! Press the Button below!

Video Lecture of Above Article is Not Available Yet

You be the First to Request! Press the Button below!

Similar Articles with Keyword 'diabetes mellitus'

Similar Articles with Keyword 'insulin analog'

Similar Articles with Keyword 'breast cancer'